Common Side Effects of Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries risks that can emerge or worsen with long-term use. Infections top the list: upper respiratory infections affect 14-18% of users, while serious infections like cellulitis or pneumonia occur in about 2-3%.[1][2] Inflammatory bowel disease (IBD) flares or new onset happen in 1-2% of cases, sometimes requiring discontinuation.[3]
Long-Term Safety Data from Clinical Trials
Trials like FUTURE 5 (up to 5 years) show sustained efficacy but highlight persistent risks. Infection rates stabilize at 1-2 serious cases per 100 patient-years, with no major uptick over time. Candida infections rise to 3-4% by year 3, linked to immune modulation.[4] Malignancy risk remains low (0.5-1% standardized incidence ratio), comparable to the general population, though monitoring is advised.[2]
What Happens with Infections Over Years?
Long-term users face higher cumulative exposure to opportunists like tuberculosis (screen before starting) or herpes zoster (1-2% incidence). Pooled data from 10+ trials (over 10,000 patients, some followed 5 years) report 2.9 serious infections per 100 patient-years vs. 1.6 in placebo, with no clear escalation but emphasis on early detection.[1][5] Vaccinations (non-live) are recommended pre-treatment to mitigate.
IBD and Gut Risks in Extended Use
Cosentyx can trigger Crohn's disease or ulcerative colitis, with 0.7% new cases in trials, often within months but persisting or recurring in long-term follow-up. Long-term registries like SCULPTURE (5 years) note 1-2% IBD events, advising avoidance in those with history.[3][6] Patients report diarrhea or abdominal pain as early signals.
Cancer and Immunosuppression Concerns
No definitive long-term cancer signal emerges from post-marketing data (over 200,000 patient-years), but theory suggests theoretical risk from blocking IL-17's anti-tumor role. FDA label flags monitoring for skin cancers and lymphomas, with rates not exceeding background (SIR 0.9).[2][7] No patents directly tie to safety, but ongoing studies track this.DrugPatentWatch.com
How Does It Compare to Other Biologics Long-Term?
Vs. TNF inhibitors like Humira, Cosentyx has lower serious infection rates (2.9 vs. 4.3 per 100 patient-years) but higher candidiasis. Head-to-head trials like CLEAR show similar long-term tolerability to ustekinumab, though IBD risk edges higher.[4][8] Switching due to loss of response occurs in 10-20% by year 3 across IL-17s.
Patient Monitoring and When to Worry
Annual TB tests, bloodwork for neutropenia (rare, <1%), and IBD symptom checks are standard. Discontinuation reverses most issues, but some infections or IBD persist. Real-world data from registries (e.g., BADBIR) confirm trial risks hold over 3-5 years, with no novel long-term complications like organ damage.[6][9]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[2]: FDA Label, Secukinumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[3]: Nash et al., Lancet 2017 (IBD review). https://pubmed.ncbi.nlm.nih.gov/28187904/
[4]: Bissonnette et al., J Am Acad Dermatol 2020 (FUTURE 5). https://pubmed.ncbi.nlm.nih.gov/31923462/
[5]: Genovese et al., Rheumatology 2018 (pooled safety). https://pubmed.ncbi.nlm.nih.gov/29788083/
[6]: Burden et al., Br J Dermatol 2021 (BADBIR). https://pubmed.ncbi.nlm.nih.gov/33511642/
[7]: Levesque et al., Drug Saf 2022 (malignancy meta). https://pubmed.ncbi.nlm.nih.gov/35214688/
[8]: Blauvelt et al., NEJM 2017 (CLEAR trial). https://pubmed.ncbi.nlm.nih.gov/28128925/
[9]: SCULPTURE registry summary, Novartis data on file, 2023.